In particular, we point to the evidence that although both ERBB2 expression levels and AKT phosphorylation levels were reduced by both drugs when used individually, we have not found a consistent combined effect on ERBB2 and AKT phosphorylation in both ERBB2+ BC cell lines. The gene discussed is ERBB2; the disease is breast cancer.